Per-protocol analysis of the PROTECT trial in 275 children aged 8–17 with new stage 3 type 1 diabetes: teplizumab preserved stimulated C-peptide better than placebo at 78 weeks (difference 0.14 nmol/l; p<0.001), with lower insulin doses.
RCTn = 275
Herold et al. Preserving beta cell function in children and adolescents with newly diagnosed stage 3 type 1 diabetes: per-protocol population analysis from the PROTECT randomised trial